Literature DB >> 6609971

Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin.

N A Kernan, R W Knowles, M J Burns, H E Broxmeyer, L Lu, H M Lee, R T Kawahata, P J Scannon, B Dupont.   

Abstract

The toxin A chain of ricin has been conjugated by a disulfide bond to a murine monoclonal antibody that recognizes the gp67kD antigen present on 95% of peripheral T lymphocytes. The immunotoxin retains both functions of its component parts: it binds to human peripheral blood lymphocytes, and it inhibits protein synthesis in a cellfree reticulocyte system. The immunotoxin has been evaluated for its ability to inhibit in vitro T lymphocyte transformation. In the presence of 20 mM NH4Cl, the immunotoxin decreases lymphocyte proliferation in response to phytohemagglutinin to less than 8% of untreated controls. The proliferative response in mixed lymphocyte culture and the development of allocytotoxic T cells is also dramatically inhibited by this immunotoxin. Monoclonal antibody alone does not inhibit these responses. Specificity of the immunotoxin has been established: the effect of the immunotoxin can be blocked by unconjugated monoclonal antibody, but not by a control monoclonal antibody that recognizes another T lymphocyte differentiation antigen or by a control monoclonal antibody that does not recognize human peripheral blood leukocytes. Treatment of human bone marrow cells with the immunotoxin preserves hematopoietic progenitor cells, as measured by granulocyte-macrophage, erythroid, and multipotential hematopoietic progenitor cell assays. These results indicate that an anti-pan T lymphocyte-ricin A chain immunotoxin is an effective agent against immunocompetent T lymphocytes in vitro, and may be an effective agent for use in clinical bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6609971

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2.

Authors:  M Better; S L Bernhard; S P Lei; D M Fishwild; J A Lane; S F Carroll; A H Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

2.  A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.

Authors:  Maksim Mamonkin; Rayne H Rouce; Haruko Tashiro; Malcolm K Brenner
Journal:  Blood       Date:  2015-06-08       Impact factor: 22.113

3.  CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.

Authors:  Diogo Gomes-Silva; Madhuwanti Srinivasan; Sandhya Sharma; Ciaran M Lee; Dimitrios L Wagner; Timothy H Davis; Rayne H Rouce; Gang Bao; Malcolm K Brenner; Maksim Mamonkin
Journal:  Blood       Date:  2017-05-24       Impact factor: 22.113

4.  An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and saporin 6: effect on T lymphocytes and hemopoietic cells.

Authors:  P L Tazzari; L Barbieri; M Gobbi; A Dinota; S Rizzi; A Bontadini; A Pession; S Tura; F Stirpe
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  In vitro and in vivo properties of an anti-CD5-momordin immunotoxin on normal and neoplastic T lymphocytes.

Authors:  G Porro; A Bolognesi; P Caretto; G Gromo; P Lento; G Mistza; T Sciumbata; F Stirpe; D Modena
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

6.  Characterization of the increased cytotoxicity of gelonin anti-T cell immunoconjugates compared with ricin A chain immunoconjugates.

Authors:  D M Fishwild; H M Wu; S F Carroll; S L Bernhard
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 7.  Prevention and management of graft-versus-host disease. Practical recommendations.

Authors:  G B Vogelsang; L E Morris
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

8.  Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models.

Authors:  H Hara; B K Seon
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

9.  Cytotoxicity against human peripheral blood mononuclear cells and T cell lines mediated by anti-T cell immunotoxins in the absence of added potentiator.

Authors:  D M Fishwild; M O Staskawicz; H M Wu; S F Carroli
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

Review 10.  Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.

Authors:  Fátima Bayón-Calderón; María L Toribio; Sara González-García
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.